期刊文献+

肉毒毒素中和抗体的研究进展 被引量:3

Perspective in Neutralizing Antibodies Against Botulinum Neurotoxin
下载PDF
导出
摘要 肉毒毒素是目前已知毒性最强的细菌蛋白质,极少量便可以致人死亡,我国每年都有散发病例出现,并且它极有可能被用于恐怖行动或被一些国家用作生物战剂。肉毒毒素中和抗体是肉毒毒素中毒后惟一有效的药物。与马源的抗毒素血清相比,重组基因工程中和抗体具有很多优势,是目前肉毒毒素预防和治疗研究的主要方向。简要综述了肉毒毒素基因工程中和抗体研究现状、保护性抗原选择、体内外中和活性检测方法及研发难点、解决方法等。 Botulinum neurotoxin is the most poisonous protein substance known and a little of toxin can be fatal.The onset of the disease appeared every year in China and it is likely to be used for bioterrorism or biowarfare by some countries.Toxin neutralizing antibody is the unique useful drug for the treatment of postexposure.Compared to antitoxin from immunized horses,genetic engineered neutralizing antibody has many advantages and has been thought as the primary development object for the prevention and therapy of botulinum toxin intoxication.This article described the perspective in neutralizing antibodies against botulinum neutrotoxin including the selection of protective antigens,the methods for detecting the activity of neutralizing antibodies,the difficulties during the development and the resolvent.
出处 《生物技术通讯》 CAS 2008年第4期597-599,603,共4页 Letters in Biotechnology
关键词 肉毒毒素 中和抗体 botulinum neurotoxin neutralizing antibody
  • 相关文献

参考文献23

  • 1Simpson L L. The origin, structure, and pharmacological activity of botulinum toxin[J]. Pharmacol Rev, 1981,33(3): 155-188.
  • 2Montecucco C, Schiavo G, Tugnoli V, et al. Botulinum neurotoxins: mechanism of action and therapeutic applications[J]. Mol Med Today, 1996,2(10):418-424.
  • 3Gill D M. Bacterial toxins: a table of lethal amounts[J]. Microbiol Rev, 1982,46(1):86-94.
  • 4Arnon S S, Schechter R, lnglesby T V, et al. Botulinum toxin as a biological weapon: medical and public health management[J]. JAMA, 2001,285(8):1059-1070.
  • 5Byrne M P, Smith L A. Development of vaccines for prevention of botulism[J]. Biochimie, 2000,82(9-10):955-966.
  • 6Amersdorfer P, Wong C, Chen S, et al. Molecular characterization of routine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries[J]. Infect lmmun, 1997,65(9):3743-3752.
  • 7DasGupta B R. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects[M]. New York: Plenum,1993:473-476.
  • 8Pless D D, Tortes E R, Reinke E K, et al. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A[J]. Infect lmmun, 2001,69:570-574.
  • 9Nowakowski A, Wang C, Powers D B, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody [J]. Proc Natl Acad Sci USA, 2002,99(17):11346-11350.
  • 10Hutson R A, Collins M D, East A K, et al. Nucleotide sequence of the gene coding for non-proteolytic Clostridium botulinum type B neurotoxin: Comparison with other clostridial neurotoxin[J]. Current Microbiol, 1994,28(2):101-110.

同被引文献30

  • 1谢忠平,崔萍芳,宋霞,李华,龙润乡,洪超,熊秋霞,李文忠,李琦涵.利用HCV多表位复合抗原制备高效价抗体[J].中国生物制品学杂志,2005,18(4):313-315. 被引量:8
  • 2Eleopra R,Tugnoli V,Quatrale R,et al.Different types ofbotulinum toxin in humans[J].Mov Disord,2004,19(Suppl8):S53-59.
  • 3Lee SK.Antibody-induced failure of botulinum toxin type Atherapy in a patient with masseteric hypertrophy[J].Derma-tol Surg,2007,33:S105-110.
  • 4Kessler KR,Skutta M,Benecke R.Long-term treatment ofcervical dystonia with botulinum toxin A:efficacy,safety,and antibody frequency.German Dystonia Study Group[J].JNeurol,1999,246:265-274.
  • 5Dressler D.Clinical features of secondary failure of botulinumtoxin therapy[J].Eur Neurol,2002,48:26-29.
  • 6Kranz G,Sycha T,Voller B,et al.Neutralizing antibodies indystonic patients who still respond well to botulinum toxintype A[J].Neurology,2008,70:133-136.
  • 7Matarasso SL.Update on the aesthetic uses of botulinum-Aneurotoxin in facial rejuvination[J].Curr Probl Dermatol,2001,13:46-53.
  • 8Jankovic J,Schwartz KS.Response and immunoresistance tobotulinum toxin injections[J].Neurology,1995,45:1743-1746.
  • 9Dressler D,Bigalke H.Botulinum toxin type B de novo ther-apy of cervical dystonia:frequency of antibody induced thera-py failure[J].J Neurol,2005,252:904-907.
  • 10Lee JC,Yokota K,Arimitsu H,et al.Production of antineu-rotoxin antibody is enhanced by two subcomponents,HA1and HA3b,of Clostridium botulinum type B 16Stoxin-haem-agglutinin[J].Microbiology,2005,151:3739-3747.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部